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Substrate-speciﬁcityncoded by the dMRP/CG6214 gene, is the Drosophila melanogaster orthologue of
the “long” human multidrug resistance-associated proteins (MRP1/ABCC1, MRP2/ABCC2, MRP3/ABCC3,
MRP6/ABCC6, and MRP7/ABCC10). In order to provide a detailed biochemical characterisation we expressed
DMRP in Sf9 insect cell membranes. We demonstrated DMRP as a functional orthologue of its human
counterparts capable of transporting several human MRP substrates like β-estradiol 17-β-D-glucuronide,
leukotriene C4, calcein, ﬂuo3 and carboxydichloroﬂuorescein. Unexpectedly, we found DMRP to exhibit an
extremely high turnover rate for the substrate transport as compared to its human orthologues. Furthermore,
DMRP showed remarkably high basal ATPase activity (68–75 nmol Pi/mg membrane protein/min), which
could be further stimulated by probenecid and the glutathione conjugate of N-ethylmaleimide. Surprisingly,
this high level basal ATPase activity was inhibited by the transported substrates. We discussed this
phenomenon in the light of a potential endogenous substrate (or activator) present in the Sf9 membrane.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe ATP-binding cassette transporters (ABC transporters), consti-
tuting one of the major classes of membrane transporters, have been
found ubiquitously in all species studied so far. The majority of these
integral membrane proteins utilise the energy of ATP-binding and
-hydrolysis to transport substrates across biological membranes [1].
Though some bacterial ABC transporters facilitate the import of
nutrients [2], all eukaryote ABC transporters characterised to date
transport their substrates from the cytoplasm either to cellular
organelles or out of the cell, thus playing essential roles in many
cellular processes such as the elimination of endo- and xenobiotics,
and the transport of excretory compounds. Besides their physiological
relevance, ABC transporters have clinical and economical signiﬁcance
as well, since some confer resistance to antibiotics, chemotherapeuticbromarone; cAMP, 3′–5′-cyclic
orescein; CFTR, cystic ﬁbrosis
ophila multidrug resistance-
curonide; GSH, reduced glu-
ultidrug resistance-associated
N-ethylmaleimide glutathione
r; Sf9, Spodoptera frugiperda
nadate
1 4665465.
atrix Research, Institute for
es, Innsbruck, Austria.
ll rights reserved.drugs and herbicides. Of the 48 genes encoding human ABC
transporters, 18 have been associated with heritable diseases. [3].
The minimal functional unit of an ABC transporter consists of
two transmembrane domains (TMD1, TMD2) and two nucleotide
binding domains (NBD1, NBD2) [4]. These are present – both in
human and in Drosophila – either as a single protein (full
transporters) or as a homo- or heterodimer of two half transpor-
ters. Each nucleotide binding domain includes three conserved
motifs: the Walker A and B motifs that are commonly observed in
ATP binding proteins [5], and the Signature C motif that is unique
to ABC transporters [6]. The transmembrane domains TMD1 and
TMD2 are composed of six transmembrane helices. A subset of the
ABCC subfamily members (“long” MRPs) possesses an additional N-
terminal transmembrane domain (TMD0) – consisting of 5
transmembrane helices – and a large cytoplasmic loop (L0)
connecting TMD0 to TMD1 [7,8]. This domain organization is
characteristic to MRP1, MRP2, MRP3, MRP6, SUR1, SUR2 and MRP7
in humans, while in Drosophila, among the 56 ABC proteins, it is
present in DSUR and DMRP only [9]. dSUR has been identiﬁed as
the functional orthologue of the mammalian SUR2 [10,11], coding
for the regulatory subunit of the ATP-sensitive potassium (KATP)
channel complex. Recent data suggest that dSUR plays a protective
role against hypoxic stress and heart failure [12]. The physiological
role of dMRP has not yet been identiﬁed.
A phylogenetic analysis revealed that DMRP is the orthologue of
human “long” multidrug resistance-associated proteins MRP1,
MRP2, MRP3 and MRP6 [13]. The typical membrane topology of
these human MRPs, which was veriﬁed experimentally for MRP1
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dMRP/CG6214 gene spans 22 kb of genomic DNA and contains 19
exonic sequences. Nine of them are alternatively spliced for two
internally variable exons giving rise to the maximum of fourteen
possible transcripts [18]. The existence of different mRNA isoforms,
each harbouring 12 exons and all but one coding for transcripts of
the same size, was experimentally demonstrated. [18]. Our
previous Northern blot and in situ hybridisation analysis, based
on the SD07655 dMRP clone coding for the 4b 8d isoform
conﬁrmed that dMRP is expressed in embryonic, larval, pupal,
and adult life stages, with enriched expression in the 0–2 h
embryos and adult brain [13]. For the biochemical characterisation
of the transporter we have expressed DMRP in the Sf9/baculovirus
expression system and demonstrated that DMRP is a vanadate-
sensitive organic anion transporter, capable of transporting the
inﬂammatory mediator LTC4, a well-known substrate of the human
“long” MRPs [13].
In the present study we provide a comparative analysis of the
functional characteristics of DMRP and the human “long” MRPs. Our
results indicate that DMRP possesses an unusually high transport
capacity for known human MRP substrates. Moreover it exhibits a
unique high level basal ATPase activity that is surprisingly inhibited
by the transported substrates, however the basal ATPase activity
can be further stimulated by the addition of some other compounds.
In the discussion section we provide a hypothesis for the above
phenomenon.
2. Materials and methods
2.1. Materials
[3H]leukotriene C4 ([3H]LTC4; 148 Ci/mmol), and [3H]β-estradiol
17-β-D-glucuronide ([3H]E217βDG; 48 Ci/mmol) were purchased
from PerkinElmer Life Sciences. 45CaCl2 (0.8 Ci/mmol) was pur-
chased from Amersham and [3H] cAMP from American Radiola-
belled Chemicals, Inc. Calcein, ﬂuo3 and carboxydichloroﬂuorescein
(CDCF) were obtained from Invitrogen — Molecular Probes. Ouabain
was purchased from Fluka. The anti-DMRP polyclonal antiserum
pAB7655 was raised against a synthetic peptide corresponding to
amino acids 209–222 of DMRP (ZYMED Laboratories Inc.) as
described [13]. The anti-MRP1 and anti-MRP2 monoclonal anti-
bodies m6 and M2I-4 were a kind gift of R. Scheper. Secondary HRP-
conjugated anti-rabbit and anti-mouse antibodies were purchased
from Jackson ImmunoResearch. Nitrocellulose membrane ﬁlters
(HAWP02500) were obtained from Millipore, and the scintillation
ﬂuid (Opti-ﬂuor) from PerkinElmer. All other compounds were
obtained from Sigma Aldrich.
2.2. Expression, membrane preparation and immunoblotting
Recombinant baculovirus containing the dMRP cDNA (SD07655)
coding for isoform 4b 8d was prepared as described previously [13].
MRP1 and MRP2 expression was generated using recombinant
baculovirus as described previously [19]. Sf9 cells were cultured and
infected with the recombinant baculovirus. After 3-days of virus
infection the Sf9 cells were harvested, the membranes were isolated
and stored at −70 °C as described by Sarkadi et al. [20]. Total
membrane protein concentrations were determined by the modiﬁed
Lowry method [21]. Gel electrophoresis and immunoblotting were
performed as described previously [20] using the anti-DMRP
polyclonal antiserum pAB7655 (1:500) or m6 and M2I-4
(1:10,000). The protein-antibody interaction was visualized by the
enhanced chemiluminescence technique (ECL, Amersham Bios-
ciences) using an anti-rabbit (1:10,000) or anti-mouse (1:10,000)
horseradish peroxidase-conjugated secondary antibodies. A quanti-
tative measure of expression was determined by densitometry ofthe immunoblots or gels stained with Coomassie Blue, using
Quantity One software (Bio-Rad).
2.3. Vesicular transport measurements
Vesicular transport of radiolabelled substrates were measured
using a rapid ﬁltration method [19,22]. Brieﬂy, isolated inside-out
Sf9 membrane vesicles containing 100 μg or 2 μg membrane protein
(as indicated) were incubated in the presence of 4 mM MgATP or
MgAMP in 150 μl of transport buffer (6 mM MgCl2, 40 mM MOPS-
Tris, pH 7.0, 40 mM KCl) at 23 °C (LTC4) or at 37 °C (E217βDG).
Incubation was stopped by the addition of 800 μl of ice-cold
washing buffer (40 mM MOPS-Tris, pH 7.0, 70 mM KCl) at the time
points indicated. Samples were ﬁltered quickly through 0.45 μm
nitrocellulose membrane ﬁlters (Millipore). The ﬁlters were washed
twice with 5 ml of cold washing buffer and the ﬁlter-bound
radioactivity was measured in scintillation ﬂuid (Opti-ﬂuor, Perki-
nElmer) using a Wallac 1409 DSA scintillation counter. ATP-
dependent transport was calculated by subtracting the activity
values obtained in the presence of AMP from those in the presence
of ATP. For these experiments, different membrane preparations
having a similar proportion of inside-out vesicles were used. The
relative amount of uptake-competent inside-out vesicles was
determined by measuring the rate of endogenous ATP-dependent
45Ca2+ uptake of each membrane preparation using a rapid ﬁltration
method described previously [22]. Transport values were corrected
for non-speciﬁc transport observed in the β-galactosidase-expres-
sing control membranes. The Michaelis–Menten kinetic parameters
of transport have been determined either from the x–y intersections
of the Lineweaver–Burk plots or from non-linear regressions of the
concentration curves using KaleidaGraph (Synergy Software), as
indicated. Data points depicted in the ﬁgures show the mean values
of at least three independent determinations conducted in dupli-
cates. Error bars depict the standard error of mean value (S.E.M.).
For the ﬂuorescent substrates, vesicular transport measurements
were performed on uptake-competent inside-out Sf9 vesicles contain-
ing 100 μg membrane protein in the presence of 6 mM MgATP or
MgAMP in 100 μl of transport buffer (6 mMMgCl2, 40 mMMOPS-Tris,
pH 7.0, 40 mM KCl) at 37 °C at the indicated substrate concentrations,
and incubation times. Samples were diluted in PBS (137 mM NaCl,
2.7 mM KCl, 8 mM Na2HPO4, 2 mM KH2PO4) and a FACSCalibur ﬂow
cytometer (Becton-Dickinson, San Jose, CA, USA), equipped with a
488 nm argon-ion laser and a 525±10 nm bandpass ﬁlter was used to
determine the ﬂuorescence intensity of the dyes accumulated in the
membrane vesicles. All datawere collected and evaluated by CellQuest
software (Becton-Dickinson, San Jose, CA, USA). A total of 10,000
vesicles were counted in each experiment. The geometric mean values
of histograms of AMP-containing samples were subtracted from the
geometric mean values of histograms of ATP-containing samples, and
ATP dependent differences were depicted in the ﬁgures. Figures
represent at least three independent determinations. The correspond-
ing standard error of mean value (S.E.M.) is depicted.
2.4. ATPase activity measurements
The vanadate-sensitive ATPase activity was measured by colori-
metric detection of inorganic phosphate liberation as described
previously [19,20]. In brief, membrane suspensions containing 30 μg
of membrane protein were incubated at 37 °C for 5 min in 150 μl of a
medium containing 40 mM MOPS-Tris, pH 7.0, 0.5 mM EGTA-Tris,
2 mM dithiothreitol, 50 mM KCl, 5 mM sodium azide, and 1 mM
ouabain. The ATPase reaction was started by the addition of 3.3 mM
MgATP. The indicated drugs were added in DMSO, except for LTC4 that
was diluted in the above assaymix. The ﬁnal concentration of DMSO in
the assaymediumwas less than 1%. The reactions were stopped by the
addition of 0.1 ml of 5% SDS. The amount of inorganic phosphate
Fig. 1. ATP-dependent E217βDG uptake into inside-out Sf9 vesicles. Concentration
dependence of E217βDG transport by DMRP at 37 °C for 0.5 min (A). Time-course of the
uptake at 1 μM E217βDG concentration at 37 °C (A inset). Lineweaver–Burk
representation of the DMRP mediated E217βDG transport (B). Inhibition of 0.5 min
E217βDG transport measured at 37 °C and 10 μM E217βDG concentration in the absence
or presence of 2 mM probenecid (PB), 50 μM benzbromarone (BB), 300 μM
indomethacin (IM) and 30 μM MK571 (C).
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optical density was read at 700 nm after 15 min incubation. ATPase
activity was calculated by the difference obtained in Pi levels between
0-min reaction (stopped immediately with SDS) and reactions afterthe 5-minute incubation periods. The differences between the ATPase
activities measured in the absence and presence of 1.33 mM vanadate
were taken and activities were corrected for non-speciﬁc activity
observed in the β-galactosidase-expressing control membranes. Data
points depict the mean values of at least three independent
determinations conducted in duplicates at a minimum. Error bars
depict the standard error of the mean value (S.E.M.).
3. Results
3.1. Transport properties of DMRP
In order to investigate the transport characteristics of DMRP we
have expressed the protein in Sf9 insect cells and studied the ATP-
dependent uptake of radiolabelled human MRP substrates, the
estrogen metabolite β-estradiol 17-β-D-glucuronide (E217βDG) and
the inﬂammatory mediator leukotriene C4 (LTC4) in isolated Sf9
membrane vesicles. The initial linear phase of the transport was
determined and the ATP-dependent transport values were corrected
with the almost negligible uptake measured in β-galactosidase
expressing control Sf9 membranes.
As demonstrated in the inset of Fig. 1A, at 37 °C, DMRP-dependent
transport of 1 μM E217βDG provided a good approximation of the
initial transport rate at 30 s. Therefore, these conditions were used to
study the concentration dependent uptake of E217βDG (Fig. 1A). The
kinetic parameters of transport were determined from the Line-
weaver–Burk plot (Fig. 1B). The apparent Km value was found to be
344±182 μMand themaximum rate of transport was 50±25 nmol/mg
of membrane protein/min. Due to the low solubility of the compound,
the concentration dependence at higher concentrations could not be
measured. Therefore these kinetic parameters have to be considered
as best estimates.
We found DMRP to exhibit an extremely high turnover rate for
LTC4 transport. To measure initial velocity, we reduced the amount of
vesicles 50 times to 2 μg total membrane protein/sample, and
measured LTC4 transport of DMRP at 23 °C. In comparison, MRP1-
dependent LTC4 transport was measured at 37 °C in vesicles contain-
ing 100 μg total membrane protein/sample. In control experiments we
measured the transport activity values of mixed vesicle preparations
(using 10 μg DMRP, and 90 μg β-galactosidase or 1 μg DMRP and 9 μg
β-galactosidase vesicles), in parallel with 10 μg or 1 μg vesicles
exclusively overexpressing DMRP. We obtained similar results for the
mixed vesicle controls and the vesicles expressing DMRP (results not
shown), suggesting that the dramatic reduction of the vesicular
content did not result in unspeciﬁc changes. Therefore, we performed
the experiments on 2 μg total membrane protein containing vesicles
obtained from DMRP over-expressing Sf9 cells. The time-course of
LTC4 uptake in 2 μg isolated vesicles at 23 °C, 50 nM LTC4 is
demonstrated in the left-hand-side inset of Fig. 2A. Kinetic parameters
of DMRP-mediated LTC4 transport were determined at 30 s, while for
MRP1 we used the generally accepted conditions reﬂecting the initial
rate of transport (100 μg protein, 23 °C, 30 s). The uptake was a
saturable function of the LTC4 concentration for both DMRP and MRP1
(Fig. 2A). We calculated the kinetic parameters from the Lineweaver–
Burk plots (Fig. 2B) as the maximum uptake rates of 3038±666 pmol/
mg of membrane protein/min and 73±15 pmol/mg of membrane
protein/min; and the apparent Km values of 231±60 nM and 187
±47 nM for DMRP and MRP1, respectively. The vesicles contained
similar amounts of over-expressed proteins as detected by Coomassie
staining (data not shown).
We also investigated the effect of known humanMRP inhibitors on
the E217βDG and LTC4 transport. The organic anions probenecid (PB),
benzbromarone (BB), indomethacin (IM), and the leukotriene receptor
antagonist MK571 effectively inhibited both E217βDG and LTC4
transport of DMRP (Figs. 1C and 2C) in a concentration range relevant
for the “long” human orthologues [19,23,24].
Fig. 3. ATP-dependent uptake of calcein into inside-out Sf9 vesicles. Experiments were
performed on 100 μg of total protein containing Sf9 vesicles prepared from DMRP
overexpressing cells. The geometric means of the ATP dependent ﬂuorescence intensity
values of 10,000 vesicles incubated at 37 °C for 0.5 min are depicted. Main ﬁgure shows
the ﬂuorescence intensity as a function of calcein concentration. Inset depicts the time-
course of calcein uptake at 1 μM calcein concentration.
Fig. 2. ATP-dependent LTC4 uptake into inside-out Sf9 vesicles. Experiments were
performed at 23 °C for 0.5 min on either 2 or 100 μg of total protein containing
membrane prepared from DMRP or MRP1 overexpressing Sf9 cells, respectively.
Concentration dependence of the DMRP and MRP1 mediated LTC4 transport (A). Time-
course of DMRP-dependent LTC4 uptake at 50 nM LTC4 concentration (A inset1). Re-plot
of the MRP1-dependent LTC4 uptake depicted in panel A (A inset 2). Lineweaver–Burk
representation of the DMRP and MRP1 mediated LTC4 transport (B). Inhibition of DMRP
dependent LTC4 transport performed at 10 nM LTC4 concentration for 0.5 min in the
absence or presence of 2 mM probenecid (PB), 50 μM benzbromarone (BB), 300 μM
indomethacin (IM) and 30 μM MK571 (C).
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adenosine mono-phosphate (cAMP), substrate of the short MRPs
(MRP4 [25] and MRP5 [26]), as well. We used 100 μg transport
competent vesicles at 37 °C at the concentration of 10–100 μM cAMP
for 10 minute incubation. In parallel we tested the LTC4 transport
activity of DMRP to monitor DMRP-function. We didn't detect any ATP
dependent transport of cAMP, suggesting that cAMP is not a substrate
for DMRP.
We used ﬂow cytometry to test the ability of DMRP to transport
ﬂuorescent human MRP substrates. We investigated the DMRP, MRP1
and MRP2 dependent uptake of calcein, Fluo3, and carboxydichloro-
ﬂuorescein (CDCF) at 37 °C, in the presence of 6 mM MgATP or
MgAMP. We measured the uptake of the ﬂuorescent substrates as a
function of the incubation time, and used incubation times within the
linear range to determine the kinetic parameters of the transports.
Due to the lack of calibration, the apparent Vmax values, always
determined under identical experimental conditions, are only
arbitrary units suitable for representing turnover differences of the
transporters. Coomassie staining revealed that the vesicles investi-
gated in FACS measurements all contained similar amount of over-
expressed proteins (data not shown).
In case of calcein we could only detect DMRP-dependent transport
activity, possibly due to the relatively low sensitivity of the assay.
Time-course showed approximate linearity up to 60 s at 37 °C (Fig. 3
inset), therefore we used these conditions to measure transport
activity as a function of calcein concentration (Fig. 3). We determined
the apparent Km of the calcein transport as 1.15±0.17 μM for DMRP
applying non-linear regression of the concentration curve.
For ﬂuo3 we could detect signiﬁcant transport activity for DMRP
and MRP2, but not for MRP1. Time-course for ﬂuo3 showed
approximate linearity up to 0.5 and 1 min for DMRP and MRP2 at
37 °C, respectively (Fig. 4A), and these conditions were used to
determine the apparent kinetic parameters (Fig. 4B). We determined
the Km values for DMRP and MRP2 from non-linear regression of the
concentration curve. The apparent Km values are 0.37±0.13 μM for
DMRP and 0.81±0.40 μM for MRP2. The difference between the
arbitrary turnover rates determined in the same experiments for
DMRP and MRP2 was remarkable. We detected 8.4 times higher
activity for DMRP than for MRP2, while the vesicles contained similar
amounts of overexpressed proteins (data not shown).
In case of CDCF, the DMRP-dependent dye accumulation was
prominent, while a moderate activity was detected for MRP2 and a
Fig. 5. ATP-dependent uptake of CDCF (carboxydichloroﬂuorescein) into inside-out Sf9
vesicles. Experiments were performed on 100 μg of total protein containing Sf9 vesicles
either prepared from DMRP or MRP2 overexpressing cells. The geometric mean values
of the ATP dependent ﬂuorescence intensity values of 10,000 vesicles incubated at 37 °C
are shown. Main ﬁgure shows the ﬂuorescence intensity as a function of CDCF
concentration incubated for 0.5 and 1 min for DMRP and MRP2, respectively. (Data has
been corrected for incubation time). Time-course of CDCF uptake at 2.5 μM concentra-
tion (inset).
Fig. 4. ATP-dependent uptake of ﬂuo3 into inside-out Sf9 vesicles. Experiments were
performed on 100 μg of total protein containing Sf9 vesicles either prepared fromDMRP
or MRP2 overexpressing cells. The geometric mean values of the ATP dependent
ﬂuorescent intensities of 10,000 vesicles incubated at 37 °C are depicted. Time-course of
ﬂuo3 uptake at 0.5 μM substrate concentration (A). Fluorescence intensity as a function
of ﬂuo3 concentration incubated for 0.5 min for DMRP and 1 min for MRP2, data
corrected for incubation time (B). Re-plot of the MRP2-dependent transport activity
(B, inset).
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investigated the activity of the aforementioned two transporters.
Time-course showed approximate linearity at 37 °C up to 0.5 and
1 min for DMRP and MRP2, respectively (Fig. 5 inset). Therefore these
conditions were applied to determine kinetic parameters of the CDCF
transport (Fig. 5). Since we detected an unspeciﬁc ATP independent
effect of CDCF on the transport assay above 50 μMCDCF concentration,
we only used and presented data up to 25 μM CDCF concentrations.
This interval included the effective concentration range of CDCF for
DMRP but not for MRP2. Therefore applying non-linear regression we
could only determine the Km values of the DMRP dependent transport
as 4.1±0.6 μM CDCF.
The ATP-dependent tracer uptake of the β-galactosidase control
membranes showed negligible background transport activity for the
three ﬂuorescent substrates (data not shown).
The MRP speciﬁc inhibitor MK571 effectively inhibited the
accumulation of calcein, ﬂuo3 and CDCF in DMRP over-expressing
Sf9 vesicles at a concentration of 30 μM (data not shown).
3.2. The ATPase activity of DMRP; effect of substrates and inhibitors
Transported substrates of ABC-transporters are known to
inﬂuence ATPase activity most commonly by increasing the rate
of ATP hydrolysis (substrate-stimulated ATPase activity) [20]. Toinvestigate the interaction between the substrates and the trans-
porter we characterised the ATPase activity of the transporter in the
absence or in the presence of different compounds (Fig. 6). The
vanadate-sensitive basal and 5 mM NEM-GS stimulated ATPase
activities of DMRP were found to show approximate linearity up to
5 min at 37 °C and 3.3 mM Mg2+ATP concentration (Fig. 6A). As
depicted in Fig. 6B, both vanadate-sensitive basal and 5 mM NEM-
GS stimulated activities were saturated above 2 mM Mg2+ATP
concentration. To further characterise the ATPase activity of the
transporter we investigated its vanadate-sensitive ATPase activity
in response to NEM-GS, probenecid, LTC4, and E217βDG (Fig. 6C).
Control membranes from cells expressing β-galactosidase had a
low level basal ATPase activity (5–8 nmol Pi/mg of membrane
protein/min) independent of the presence of the tested compounds
(data not shown). The vanadate-sensitive ATPase activity of DMRP
in the absence of any substrate was unusually high (68–75 nmol
Pi/mg of membrane protein/min) compared to that of human MRP1
(6–8 nmol Pi/mg of membrane protein/min), [19,23]. The basal
activity could be stimulated 1.9 fold in the presence of the synthetic
glutathione-conjugate, NEM-GS (2.5 mM), and 1.8 fold in the presence
of the organic anion probenecid (1 mM) (Fig. 6C). Interestingly, all of
the investigated DMRP transport substrates (LTC4, calcein, and
E217βDG) inhibited the basal ATPase activity. The inhibited (residual)
activity was 46% for LTC4, 77% for calcein (data not shown) and 12.5%
for E217βDG, at the highest concentrations used (Fig. 6C). The IC50
values for LTC4 and E217βDG in ATPase activity measurements
correlated well with the apparent Km values determined in the
transport experiments. The speciﬁc MRP inhibitor MK571 inhibited
both the NEM-GS stimulated and the basal ATPase activity in a con-
centration dependent manner with IC50 values of 1.05 and 2.05 μM,
respectively (Fig. 6D).
4. Discussion
The present study focused on a detailed characterisation of DMRP,
the only Drosophila melanogaster orthologue of the human “long”
MRPs (MRP1, 2, 3, 6, and 7), providing an analysis of Drosophila MRP
transport and ATPase activities by comparing them to those of its
human orthologues.
Fig. 6. Effect of modulators on the vanadate-sensitive ATPase activity of DMRP. Time-course of the vanadate-sensitive ATPase activity of DMRP at 37 °C and 3.3 mM Mg2+ATP
concentration in the presence or absence of 5 mMNEM-GS (A). Mg2+ATP concentration dependence of the vanadate-sensitive ATPase activity of DMRP at 37 °C incubated for 5 min in
the presence or absence of 5 mM NEM-GS (B). DMRP dependent vanadate-sensitive ATPase activity at 37 °C, 3.3 mM Mg2+ATP concentration incubated for 5 min in the absence or
presence of various concentration of the following compounds: NEM-GS (diamond), probenecid (triangle), LTC4 (square), E217βDG (circle) (C). DMRP-dependent vanadate-sensitive
ATPase activity as a function of MK571 concentration in the absence (triangle) or in the presence (diamond) of 5 mM NEM-GS (D).
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Sf9/baculovirus expression systemand the ability of DMRP to transport
different humanMRP substrates, such as E217βDG, LTC4, calcein, ﬂuo3
and CDCF were tested in vesicular transport experiments.
Human “long” MRPs were shown to transport E217βDG [27–33].
The majority of these proteins show modest capacity but low Km
values (apparent Km of 10–70 μM) for E217βDG with the exception of
MRP2, which shows high Km value but is considered to have the
highest transport rate for this substrate [34]. We detected 4.6 times
higher maximal transport rate for DMRP than for MRP2 in the
E217βDG vesicular transport experiments, while the expression level
of DMRP in vesicles used for determination of E217βDG transport
kinetic parameters was approximately one-fourth of the expression of
MRP2. Therefore the maximal transport rate of DMRP is approxi-
mately 18 times higher than that of MRP2. We found that the Km of
DMRP for this substrate is relatively high, thereforewe consider DMRP
as a unique high capacity transporter of E217βDG, resembling the
properties of MRP2, as both transporters show high Km and transport
rate values.
All “long” MRPs are capable of transporting LTC4 with different
transport characteristics [24,29,31,32,35]. We have investigated the
LTC4 transport properties of DMRP, and found the maximal transport
rate of DMRP for LTC4 approximately 40 times higher than that of thephysiologically relevant MRP1, while DMRP possesses slightly higher
Km value for LTC4 than MRP1.
It was previously shown that MRP1 is capable of transporting
calcein [36], while ﬂuo3 is transported by both MRP1 and MRP2 [37–
39]. CDCF was proven to be a substrate for MRP2 and MRP5 [40]. We
investigated the ability of DMRP to transport these ﬂuorescent
substrates of the human MRPs, and determined their apparent Km
values. We detected a high turnover rate for DMRP for all the three
ﬂuorescent substrates, while MRP2 investigated in parallel showed
only moderate transport activity for ﬂuo3 and CDCF (though these
transporters were expressed at similar levels).
We investigated the inhibitor proﬁle of the DMRP-dependent
transport and found that the organic anions probenecid, benzbromar-
one, indomethacin, and the leukotriene receptor antagonist MK571
exhibited potent inhibitory effects on DMRP transport at concentra-
tions that negatively impact the transport properties of the human
orthologues as well [19,22–24,34].
The ATPase activity measurements showed that DMRP has the
highest basal activity (68–75 nmol Pi/mg membrane protein/min) of
anyMRP studied to date in Sf9membrane vesicle preparations [19,23].
This unusually high basal activity of DMRP could be further stimulated
by NEM-GS and probenecid. Surprisingly, all of the investigated DMRP
transport substrates inhibited the basal ATPase activity in a
408 F. Szeri et al. / Biochimica et Biophysica Acta 1788 (2009) 402–409concentration dependent manner for the whole effective concentra-
tion range (Fig. 6C).
Collectively, these observations demonstrate that DMRP reﬂects
many properties of the human “long” MRPs including substrate and
inhibitor speciﬁcity. However, there are several unique features of
DMRP revealed by the present study: i) compared to the human
transporters, DMRP exhibits a much higher transport activity; ii)
DMRP has an unusually high basal ATPase activity; iii) the investigated
DMRP substrates inhibit the basal ATPase activity.
The remarkable activity of DMRP compared to that of the human
transporters may partially originate from the fact that it is an insect
protein expressed in a similar host cell. In addition, we hypothesise
that DMRP in the Sf9 membrane is already in an activated state. This
could either originate from the presence of endogenous substrate(s) or
activator molecule(s) characteristic of Sf9 cells. This activation is
presumably not complete, since NEM-GS and probenecid can evoke
further activation of the ATPase activity. Nevertheless, this partial
activation would imply that the transporter efﬁciently hydrolyses ATP
even in the absence of any external substrate, though an external
substrate may successfully compete with the endogenous activator. If
such a competitive external substrate is added and the potential of the
external substrate to trigger ATP hydrolysis is weaker than that of the
endogenous one, an apparent inhibition of the ATPase activity may be
detected. Investigations of puriﬁed DMRP reconstituted in different
membrane environments would shed light onto the relevance of the
above hypothesis. The work aiming to obtain active puriﬁed protein is
on the way.
Another question is whether the high basal activity detected in
vitro has any relevance in vivo. It is quite unlikely that an organism
would pay the cost for having such an ATP depleting active transporter
unless it had a fundamental role in its homeostasis. Since DMRP knock
out animals are viable and fertile (http://ﬂybase.org, FlyBase ID:
FBti0024660, FBti0057681) and dMRP cDNA is present ubiquitously
[13], it seems that this is not the case. It is more likely that DMRP does
not possess such a high basal activity in its natural environment, e.g.,
due to the lack of such an activator or the presence of some negative
regulatory mechanisms.
The present article provides information on the characteristics of
DMRP revealing that DMRP possesses combined features of its human
orthologues, however exhibiting a remarkably higher activity. These
features make DMRP a valuable model protein for further studies to
reveal the mechanistic features of MRPs, especially for investigations
that require high turnover.
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